- Home
- KOD vs ATXS Comparison
KOD vs ATXS Comparison
Compare KOD & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | ATXS |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 732.4M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KOD | ATXS |
|---|---|---|
| Price | $26.05 | $13.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 6 |
| Target Price | ★ $26.57 | $24.33 |
| AVG Volume (30 Days) | ★ 1.1M | 901.5K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $706,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $3.56 |
| 52 Week High | $31.18 | $13.29 |
Technical Indicators
Market Signals| Indicator | KOD | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 58.37 |
| Support Level | $23.92 | $12.73 |
| Resistance Level | $28.11 | $13.29 |
| Average True Range (ATR) | 2.28 | 0.18 |
| MACD | -0.49 | -0.02 |
| Stochastic Oscillator | 27.41 | 64.84 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.